Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,380 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- OncoTree
- PROSTATE
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,984 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Feb 14, 2018 |
| clinicaltrials |
| NCT01289067 | Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | completed | Phase 2 | 13 | William K. OhOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | terminated | Phase 2 | 22 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003516 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | terminated | Phase 2 | 16 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02097303 | Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis(eRADicAte) | completed | Phase 2 | 36 | Carolina Research Professionals, LLCOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00003534 | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00983710 | Prostate Cancer Symptom Management for Low Literacy Men | completed | Phase 2 | 108 | Baylor College of MedicineOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01105338 | Lycopene or Green Tea for Men at Risk of Prostate Cancer(ProDiet) | completed | Phase 2 / Phase 3 | 126 | University of BristolOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00814788 | Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer(UCDCC#215) | completed | Phase 2 | 24 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01199146 | Abiraterone Post Ketoconazole for Prostate Cancer | completed | Phase 2 | 42 | University of California, San FranciscoOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT03392233 | Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors | recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00003533 | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00348816 | Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00630344 | RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00307294 | Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | completed | Phase 2 | 40 | University of PittsburghOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00524589 | Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT03344822 | Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients(TePSMAG-68) | unknown | Phase 2 / Phase 3 | 33 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02793219 | Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02793765 | Docetaxel Followed by Provenge in Metastatic Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00844792 | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01992042 | Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01288534 | Hypofractionated Stereotactic Body Radiation Therapy (SBRT) | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01756638 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer | completed | Phase 2 | 48 | Janssen Research & Development, LLCINDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT00887458 | A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | completed | Phase 2 | 46 | Johns Hopkins UniversityOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT02724618 | Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT) | unknown | Phase 2 | 64 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00953225 | Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer(vit D & PCa) | completed | Phase 2 | 83 | VA Office of Research and DevelopmentFED | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00480857 | Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy | terminated | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00195039 | Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | completed | Phase 2 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03297385 | Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation(DARANA) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 0 | Sep 29, 2017 | clinicaltrials |
| NCT01834651 | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | completed | Phase 2 | 17 | Edwin Posadas, MDOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02844699 | A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00078585 | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | completed | Phase 2 | 120 | Bavarian NordicINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00585962 | Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate | completed | Phase 2 | 57 | Massachusetts General HospitalOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT00678054 | Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) | completed | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02810886 | Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management(ProsPERo) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT02452307 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 36 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT02391051 | Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial(FOKAL-BT) | recruiting | Phase 2 | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Aug 11, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Feb 26, 2018source: clinicaltrials